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MAPK/AP-1–dependent regulation of PAI-1 gene expression
by TGF-b in rat mesangial cells.
Background. Receptor-regulated Smads and/or mitogen-
activated protein kinases (MAPKs) are involved in transform-
ing growth factor-b (TGF-b)–induced expression of various
genes, including plasminogen activator inhibitor-1 (PAI-1). Be-
cause the sequence of the promoter region in rat PAI-1 gene
differs from that in the human gene, we examined the mecha-
nisms of TGF-b–induced rat PAI-1 expression in rat mesangial
cells.
Methods. TGF-b1–induced PAI-1 and c-fos mRNA expres-
sions were determined by Northern blot analysis. Activation of
MAPKs and Smad proteins was evaluated by an immunoblot
analysis. DNA binding activities of nuclear protein were exam-
ined by using an electrophoretic mobility shift assay (EMSA).
The activities of PAI-1 promoter were measured by a luciferase
reporter assay.
Results. Extracellular-regulated kinase (ERK) and c-Jun
NH-terminal kinase (JNK) phosphorylation, c-fos mRNA ex-
pression, and activator protein-1 (AP-1) DNA binding activ-
ity stimulated by TGF-b1 were completely suppressed by the
ERK kinase (MEK) inhibitors. EMSA and reporter analysis
revealed that an AP-1–like sequence located in the proximal
region of the rat PAI-1 promoter was the target for TGF-b1,
and the disruption of this AP-1–like sequence suppressed basal
and TGF-b1–induced promoter activation. TGF-b1 also stimu-
lated nuclear translocation of Smads and binding to palindromic
Smad binding element (SBE) located in the rat PAI-1 promoter,
without being affected by MEK inhibitor. Point mutation and
deletion of palindromic SBE did not affect TGF-b1–induced
rat PAI-1 promoter activity. Moreover, interferon-c (IFN-c) in-
hibited TGF-b1–induced PAI-1 expression through selectively
suppressing the ERK-AP-1 pathway.
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Conclusion. These results suggest that the essential require-
ment of MAPK/AP-1 activation for TGF-b1–induced PAI-1 ex-
pression is unique to rat mesangial cells.
Transforming growth factor-b (TGF-b) has a wide
range of biologic functions such as the regulation of cell
growth, differentiation, and immunologic response in var-
ious types of cells [1, 2]. The involvement of TGF-b in the
pathogenesis of fibrotic diseases has been proposed based
on its capacity to stimulate the production of extracellular
matrix (ECM) proteins and to regulate their metabolism
[3]. Plasminogen activator inhibitor-1 (PAI-1) is a glyco-
protein of the serpin superfamily and one of the major
targets regulated by TGF-b [4, 5]. Induction of PAI-1
by TGF-b in pathologic states results in an inhibition of
protease-dependent fibrinolytic activity and an accumu-
lation of ECM proteins, leading to tissue fibrosis. Thus, it
is important to clarify the mechanism of TGF-b–induced
PAI-1 production.
TGF-b exerts its multiple biologic actions by interac-
tion with a heteromeric complex of two types of trans-
membrane serine-threonine kinase receptors (types II
and I). Upon ligand binding to the receptor complex,
the activated TGF-b receptor complex transiently in-
teracts with receptor-activated Smads, which propagate
TGF-b signaling transduction through phosphorylation.
After Smad2 and Smad3 bind to the common effector
Smad4, Smad4-containing heteromeric Smad complexes
translocate from the cytoplasm into the nucleus, where
they directly bind to DNA or interact with other tran-
scriptional factors to regulate the promoter activities of
TGF-b targeting genes [6–8]. Recent studies indicate that
the hetero-oligomeric complex of Smad3/Smad4 binds
to the GACACC, GTCTAGAC, or AG(C/A)CAGACA
sequences. The last sequence, termed the CAGA box,
was found in the promoter region of the human PAI-
1 gene. TGF-b–stimulated Smad3/Smad4 complex was
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shown to directly bind to the CAGA box and up-regulate
human PAI-1 promoter activity [9, 10]. On the other hand,
mitogen-activated protein kinases (MAPKs) including
the extracellular signal-regulated kinases (ERKs), the c-
jun NH2-terminal kinases (JNKs) and the p38 MAPK
pathway have also been proposed as an important signal-
ing cascade of TGF-b in a number of different types of
cells, including glomerular mesangial cells [11, 12]. Pre-
vious studies indicated that the activation of the MAPK
pathway by TGF-b modulated the expression of several
genes, including human PAI-1 gene through the activa-
tion of its downstream transcription factors such as acti-
vator protein-1 (AP-1) [5, 12, 13]. Thus, both Smads and
AP-1 are considered to cooperate positively in TGF-b1–
induced human PAI-1 gene expression. However, there
are sequence differences among species in the promoter
region of the PAI-1 gene. Indeed, sequence comparison
between human and rat PAI-1 promoter revealed only
60% identity in the 800 bp region upstream from the
transcription initiation site of PAI-1 promoter [14]. For
example, the complete AG(C/A)CAGACA sequence ob-
served in human PAI-1 promoter is not conserved in rat
PAI-1 promoter, suggesting that the mechanism of regu-
lation might be distinct in TGF-b–induced rat PAI-1 gene
expression.
In the present study, we demonstrated that both the
MAPK pathway and Smad pathway are simultaneously
activated by TGF-b1 in rat glomerular mesangial cells.
We identified the target sequence of each pathway for the
rat PAI-1 promoter. MEK-ERK–derived AP-1 complex
binds to an AP-1–like sequence, which is located in the
proximal region of rat PAI-1 promoter, and then stim-
ulates promoter activity. TGF-b1–induced Smad com-
plex binds to palindromic Smad binding element (SBE)
of the rat PAI-1 promoter, which is not conserved
in humans, and does not affect the promoter activity.
Moreover, we demonstrated that interferon-c (IFN-c)
inhibited TGF-b–induced PAI-1 mRNA expression by
selectively suppressing the ERK-AP-1 pathway but not
the Smad pathway. Taken together, these results indicate
that the MAPK-AP-1 pathway is essential for TGF-b–
induced PAI-1 gene expression in rat mesangial cells.
METHODS
Materials
Human recombinant TGF-b1 and recombinant rat
IFN-c were obtained from R&D Systems (Minneapo-
lis, MN, USA). Antiphospho MAPKs and MEK in-
hibitor PD98059 were bought from New England Biolabs
(Beverly, MA, USA). Anti-MAPKs, c-jun, c-fos, pan-
fos, pan-jun, Smad2/3, and Smad4 antibodies were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Nucleoporin p62 monoclonal antibody was ob-
tained from Transduction Laboratories (San Diego, CA,
USA). MEK inhibitor U0126 and consensus oligonu-
cleotide sequence of AP-1 were bought from Promega
(Madison, WI, USA). [a-32P] deoxycytidimine triphos-
phate (dCTP) and [c-32P] adenosine triphosphate (ATP)
were bought from New England Nuclear (Boston, MA,
USA). N-terminal Flag-tagged Smad3 (Flag-N-Smad3)
and its mutants in which three serines were mutated
to alanine (Flag-N-Smad3A) or aspartic acid (Flag-N-
Smad3D) were kindly provided by Dr. Harvey F. Lodish
[15].
Cell culture
Rat glomerular mesangial cells, obtained from
glomeruli isolated from Sprague-Dawley rats, were
grown in RPMI-1640 medium containing 20% fetal
bovine serum (FBS) at 37◦C in a humidified 95% air/5%
CO2 atmosphere as previously described [16]. Mesan-
gial cells were used at between passages 4 and 8.
For experiments, subconfluent rat mesangial cells were
starved for 48 hours by incubation with FBS-free RPMI-
1640 medium containing 0.2% bovine serum albumin
(BSA) and then incubated with an experimental medium
(RPMI-1640 medium with 0.2% BSA and 20 mmol/L
Hepes, pH 7.4).
Immunoblot analysis
Mesangial cells were lysed in an ice-cold lysis buffer
containing 150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH
8.0), 0.1% sodium dodecyl sulfate (SDS), 1% Non-
idet P-40, and protease inhibitor cocktail (Boehringer
Mannheim, Mannheim, Germany). Cell lysates were
subjected to SDS-polyacrylamide gel electrophoresis
(PAGE) and transferred to polyvinyl difluoride (PVDF)
membranes (Immobilon, Bedford, MA, USA). The
membranes were probed with the indicated antibodies.
Immunoreactive bands were detected with secondary an-
tibody and developed with an enhanced chemilumines-
cence detection system (New England Biolabs).
Northern blot analysis
Total RNA was isolated from cells with Trizol Reagent
(Gibco BRL, Grand Island, NY, USA) following the
manufacturer’s protocol. Northern blot analysis was per-
formed as previously described [17]. Briefly, 12 lg of
RNA was electrophoresed through 1% formaldehyde-
agarose gels and transferred onto nylon membranes
(Nytran) (Schleider & Schuell, Dassel, Germany). Af-
ter fixation by ultraviolet cross-linking, the membranes
were hybridized with [a-32P] ATP-labeled rat PAI-1, c-
fos, and Smad7 cDNAs by using a Bca BEST labeling kit
(Takara, Otsu, Japan), and then subjected to autoradiog-
raphy. The membranes were reprobed with human acidic
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ribosomal phosphoprotein PO (36B4) cDNA as an inter-
nal standard.
Immunocytochemical analysis
Rat mesangial cells on non-coated sterile cover slides
in 12-well plates were subjected to the indicated stim-
ulations. Cells were washed twice with ice-cold phos-
phate buffered saline (PBS) and fixed for 3 minutes with
methanol at −20◦C. After blocking with PBS-2% BSA
for 20 minutes, cells were incubated with the primary an-
tibody for Smad2/3 (1:500 dilution) for overnight at 4◦C,
and then washed followed by incubation with a biotiny-
lated secondary antibody (1:500 dilution) (Vector Labs,
Peterborough, UK). Immunoreactive stains were devel-
oped with a VectaStain ABC kit (Vector Labs).
DNA constructs
To construct a reporter for rat PAI-1 promoter, a frag-
ment of the rat PAI-1 promoter (bases −757/+48) was
amplified by polymerase chain reaction (PCR) using rat
genomic DNA as a template [4]. The PCR product was
subcloned into PGL2 Basic luciferase expression vec-
tor (Promega) at MluI-XhoI sites. To produce 5′-deleted
reporter constructs, the rat PAI-1 promoter (bases
−757/+48) subcloned in PGL2 Basic was amplified by
PCR using the appropriate 5′ primers and then subcloned
into PGL2 Basic. A mutation of the reporter sequence
(bases −390/+48) was made by using a Quick ChangeTM
Site-Directed Mutagenesis kit (Stratagene, La Jolla,
CA, USA) using a pair of oligonucleotides (−76/−42)
and (−281/−250) substituting TGAGTTCA for TGTGT
TTG and GTCTAGAC for CTCTAGAC, respectively.
The sequence authenticity of these plasmids was con-
firmed using a rhodamine terminator cycle sequence sys-
tem (ABI) and an ABI Prism 310 genetic analyzer.
Transient transfection and luciferase assay
Rat mesangial cells were grown to 70% to 80% con-
fluence in RPMI-1640 medium supplemented with 20%
FBS on 6-well plates. Transient transfections with the in-
dicated luciferase reporter constructs were performed
with LipofectAMINE reagent (Invitrogen, Carlsbad,
CA, USA). Cytomegalovirus-b (CMV-b)–galactosidase-
containing plasmid was cotransfected as a control for
transfection efficiency. Three hours after transfection,
the cells were recovered in culture medium containing
20% FBS for 16 hours, and then starved with FBS-free
RPMI-1640 medium containing 0.2% BSA for 24 hours,
followed by TGF-b1 stimulation for 16 hours. In the ex-
periments using IFN-c, cells were pre-treated with IFN-c
for 3 hours followed by the stimulation with TGF-b1. Af-
ter being washed twice with cold PBS, cells were lysed in
200 lL of reporter lysis buffer (Promega). Twenty micro-
liter aliquots of extracts were used to measure luciferase
activity with a Luciferase Assay System (Promega)
and a luminometer (Auto LUMIcounter Nu1422ES)
(Nition, Tokyo, Japan). Cotransfected b-galactosidase
activity was determined and used to normalize the lu-
ciferase activity. Results are expressed as ratio (fold in-
duction) of normalized luciferase activities.
Nuclear extraction and electrophoretic mobility shift
analysis (EMSA)
Nuclear extracts were prepared as previously de-
scribed [18]. In brief, cells were lysed with the addition of
a hypotonic buffer [10 mmol/L Hepes, pH 7.8, 0.1 mmol/
L ethylenediaminetetraacetic acid (EDTA), 15 mmol/L
KCl, 2 mmol/L MgCl2, 1 mmol/L dithiothreitol (DTT),
and proteinase inhibitor cocktail] containing 0.8%
Nonidet P-40, and centrifuged at 6000g for 10 min-
utes. Pellets were resuspended with a high-salt buffer
(20 mmol/L Hepes, pH 7.8, 420 mmol/L NaCl, 1.5 mmol/L
MgCl2, 0.5 mmol/L DTT, 0.2 mmol/L EDTA, and 25%
glycerol), rotated for 30 minutes at 4◦C, and then
centrifuged at 13,000g for 30 minutes. Supernatants were
used as nuclear proteins for EMSA and immunoblot
analysis. Three micrograms of nuclear proteins were
incubated with 1 lg of poly (dI-dC) in a binding buffer
(10 mmol/L Tris, pH 7.5, 50 mmol/L NaCl, 1 mmol/L
DTT, 1 mmol/L EDTA, and 5% glycerol) for 30 minutes
and then reacted with AP-1 consensus oligonucleotides
(Promega) and indicated synthetic complementary
oligonucleotides from rat PAI-1 promoter at room
temperature for 20 minutes, which were labeled by
reactions with [c-32P] ATP and T4 oligonucleotide
kinase (New England Biolabs). The reaction mixtures
were electrophoresed through 4% polyacrylamide gels
and were subjected to autoradiography. Competition
experiments were performed after the addition of an ex-
cess amount of the indicated unlabeled double-stranded
oligonucleotides to the reaction mixtures. For supershift
analysis, the indicated antibodies were preincubated
at 37◦C for 30 minutes before the reactions with the
radiolabeled probes. The sequences of plus-strand DNAs
used as probes in EMSA were as follows: AP-1 con-
sensus 5′-CGCTTGATGAGTCAGCCGGAA-3′; Sp1
consensus 5′-ATTCGATCGGGGCGGGGCGAGC-3′;
rat PAI-1 AP-1–like sequence 5′-TGGGGCTGGAACA
TGAGTTCATCTATTTCC-3′; rat PAI-1 AP-1–like mu-
tant sequence 5′-TGGGGCTGGAACATGTGTTTG
TCTATTTCC-3′ [19]; rat PAI-1 palindromic SBE
sequence 5′-TACCGCCAAGGGTCTAGACGACCGA
CCAGC-3′; rat PAI-1 palindromic SBE mutant sequence
5′-TACCGCCAAGGCTCTAGACGACCGACCAGC-
3′ [9]; and rat PAI-1 SBE-like sequence 5′-TACCGCCA
AGGGTCTAGACGACCGACCAGC-3′.
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Fig. 1. Transforming growth factor-b1 (TGF-b1) stimulates mitogen-
activated protein kinase (MAPK) phosphorylation in rat mesangial
cells. (A) TGF-b1 stimulated extracellular-regulated kinase (ERK) and
cJun NH-terminal kinase (JNK) phosphorylation in a time-dependent
manner. Cells were stimulated with TGF-b1 (2.5 ng/mL) for indicated
time intervals. (B) TGF-b1 stimulated ERK and JNK phosphorylation
in a dose-dependent manner. Cells were stimulated with indicated con-
centrations of TGF-b1 for 10 minutes. Twenty microliters of total cell
lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Immunoblotting was performed using
indicated antibodies.
Statistical analysis
Results are expressed as mean ± SD. Analysis of vari-
ance (ANOVA) with subsequent Scheffe´ test was used to
determine the significance of difference in multiple com-
parisons, and statistical significance was defined as P <
0.05.
RESULTS
TGF-b1 stimulates ERK and JNK phosphorylation, c-fos
mRNA expression, and AP-1 DNA binding activity
We first examined the effect of TGF-b1 on the
activation of the MAPK family by Western blot analysis.
ERK and JNK were rapidly phosphorylated by TGF-
b1, with the peak stimulation at 10 minutes (Fig. 1A), in a
c-fos
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36 B4
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Fig. 2. Blockade of extracellular-regulated kinase (ERK) kinase
(MEK) activity suppresses transforming growth factor-b1 (TGF-b1)–
induced rat c-fos mRNA expression and activator protein-1 (AP-1)
DNA binding activity. (A) TGF-b1 induced c-fos mRNA expression.
Cells were stimulated with TGF-b1 (2.5 ng/mL) for indicated time inter-
vals. (B) PD98059 inhibited TGF-b1–induced c-fos mRNA expression.
Cells were incubated with or without PD98059 for 90 minutes prior
to the exposure to TGF-b1 for 30 minutes. Northern blotting was per-
formed as described above. (C) TGF-b1 stimulated AP-1 DNA binding
activity in a time-dependent manner. Cells were stimulated with TGF-
b1 (2.5 ng/mL) for indicated time intervals. Nuclear extracts from cells
were subjected to electrophoretic mobility shift assay (EMSA) using
a [c32P]-labeled double-stranded consensus AP-1 oligonucleotide. Su-
pershift assay was performed using indicated antibodies. (D) PD98059
inhibited TGF-b1–induced AP-1 DNA binding activity. Cells were in-
cubated with or without PD98059 for 90 minutes prior to the exposure
to TGF-b1 for 1 hour. EMSA was performed as described above. A rep-
resentative one of three independent experiments is shown. The data
are expressed as mean ± SD (N = 3). ∗P < 0.05 vs. control; ∗∗P < 0.05
vs. TGF-b1.
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Fig. 2. (continued)
dose-dependent (2.5 ng/mL maximum) manner (Fig. 1B),
whereas an increase in phosphorylation of p38 MAPK
was not observed (data not shown). As shown in
Figure 2A, TGF-b1 increased c-fos mRNA expression
in a time-dependent manner, with the peak stimulation
at 30 minutes. A specific inhibitor of MEK, PD98059,
inhibited TGF-b1–induced c-fos mRNA expression
(Fig. 2B). EMSA revealed that TGF-b1 stimulated AP-
1 DNA binding activity in a time-dependent manner
(60 minutes maximum). TGF-b1-induced DNA nuclear
protein complex was shifted by the specific antibodies
against c-fos and c-jun proteins (Fig. 2C). PD98059 also
inhibited TGF-b1–induced AP-1 DNA binding activity
in rat mesangial cells (Fig. 2D). Moreover, TGF-b1 did
not affect the expression of any jun family proteins, in-
cluding c-jun, jun B, and jun D, after TGF-b1 stimulation
(data not shown).
Blockade of MEK activity abrogates TGF-b1–induced rat
PAI-1 mRNA expression
To investigate the role of the TGF-b1–induced MEK-
ERK activation in rat PAI-1 mRNA expression, we
examined the effect of MEK inhibitors on TGF-b1–
induced rat PAI-1 mRNA expression in rat mesangial
cells. TGF-b1 stimulated PAI-1 mRNA expression in a
time-dependent manner, with a peak at 1 hour (Fig. 3A),
and in a dose-dependent manner with a maximal stimula-
tion at 2.5 ng/mL (Fig. 3B). PD98059 significantly inhib-
ited TGF-b1–induced PAI-1 mRNA expression in a dose-
dependent manner (Fig. 3C). Similarly, another specific
MEK inhibitor, U0126, also suppressed TGF-b1–induced
PAI-1 expression in a dose-dependent manner (Fig. 3D).
These results suggest that TGF-b1–induced activation of
the MEK-ERK pathway is required for rat PAI-1 gene
expression in mesangial cells.
Blockade of MEK activity does not influence TGF-b1–
induced Smads nuclear accumulation or DNA binding to
palindromic SBE in rat PAI-1 promoter
TGF-b is known to stimulate gene expression via ac-
tivating Smad proteins. Recent data suggest that the
Smads are also phosphorylated by hepatocyte growth
factor (HGF) and epidermal growth factor (EGF) in a
MEK-ERK–dependent manner [20, 21]. Whether TGF-
b–induced MEK-ERK activation modulates Smad ac-
tivation has not been elucidated in rat mesangial cells.
To clarify this issue, we examined the effect of PD98059
on TGF-b–induced endogenous Smads activation in rat
mesangial cells. In the immunocytochemical study us-
ing antisera against Smad2 and Smad3, TGF-b1 stim-
ulated the nuclear accumulation of these Smads, while
PD98059 (10 lmol/L) did not affect TGF-b1–induced
Smad nuclear accumulation (Fig. 4A). Western blot anal-
ysis using nuclear proteins also confirmed that PD98059
did not affect TGF-b1–induced nuclear accumulation of
Smad2, Smad3, or Smad4 (Fig. 4B). Higher concentra-
tion of PD98059 (50 lmol/L) also had no effect (data not
shown).
Recently, the AG(C/A)CAGACA sequences, which
have been identified as Smad3 and Smad4 binding sites,
were found in three different regions within 800 bp
upstream from the transcription initiation site of the
human PAI-1 promoter [10]. However, no SBEs have
been identified in rat PAI-1 promoter. In spite of our
search for the sequences of reported rat PAI-1 pro-
moter, we could not find complete AG(C/A)CAGACA
sequences in the region within 1 kb upstream from
the transcription initiation site of rat PAI-1 promoter.
A recent report characterized the gagaGTCTGGA-
CacgtggGGAGTCAgccg sequence between −688 and
−660 upstream of the transcription initiation site of hu-
man PAI-1 promoter as a new Smads (Smad3 and Smad4)
binding element [22]. Although we found gagaGTCTG-
GCCccatgtggGGAGTCAgagg sequence between −626
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and −596 upstream of the transcription initiation site of
rat PAI-1 promoter, EMSA revealed that TGF-b1 failed
to increase nuclear protein binding to the 42 bp oligonu-
cleotide of an rat PAI-1 promoter including this potential
SBE (data not shown). In an additional search of the rat
PAI-1 promoter sequences, we found an 8 bp GTCTA-
GAC palindromic DNA sequence, which was identified
as an optimal SBE by PCR-based selection procedure [9],
located at between −267 and −260 upstream of the tran-
scription initiation site of the rat PAI-1 promoter. This
GTCTAGAC palindromic DNA sequence was found in
the promoter of TGF-b–targeted gene and is character-
ized as a Smad3 and Smad4 binding site [23]. Interest-
ingly, this palindromic SBE was not found in the human
PAI-1 promoter. As shown in Figure 4C, EMSA using an
oligonucleotide (−280/−251) containing this 8 bp palin-
dromic SBE of rat PAI-1 promoter as a probe revealed
that TGF-b1 stimulated the binding of nuclear proteins to
this oligonucleotide in rat mesangial cells. This band was
abolished by the addition of anti-Smad2/3 antibody and
supershifted by the anti-Smad4 antibody but not by anti-
pan-fos, anti-pan-jun or anti-Sp1 antibodies, indicating
that TGF-b1–induced Smads complex binds this palin-
dromic SBE without forming a complex with AP-1 or
Sp1 components.
In order to investigate whether TGF-b–induced ac-
tivation of the MEK-ERK pathway modulates Smad
DNA binding activity, we next examined the effect of
PD98059 on TGF-b–induced Smad DNA binding activ-
ity in mesangial cells. As shown in Figure 4D, PD98059
(10 lmol/L) did not affect the binding of Smads to this
palindromic SBE. Higher concentration of PD98059 (50
lmol/L) also had no effect (data not shown). These re-
sults suggest that TGF-b1–activated MEK-ERK did not
affect DNA binding of Smads.
TGF-b1 stimulates rat PAI-1 promoter through the
AP-1–like sequence but not palindromic SBE
To determine the TGF-b responsive region in rat PAI-
1 promoter, we performed reporter analysis using the
deletion constructs of rat PAI-1 promoter. The reporter
Fig. 3. Blockade of extracellular-regulated kinase (ERK) kinase
(MEK) activity suppresses transforming growth factor-b1 (TGF-b1)–
induced rat plasminogen activator inhibitor-1 (PAI-1) mRNA expres-
sion. TGF-b1 induced PAI-1 mRNA expression in (A) a time- and (B) a
dose-dependent manner. Cells were treated with TGF-b1 (2.5 ng/mL)
for indicated time intervals and concentrations for 1 hour. PD98059
(C) or U0126 (D) inhibited TGF-b1–induced PAI-1 mRNA expres-
sion. Cells were preincubated with or without PD98059 (C) or U0126
(D) at indicated concentrations for 90 minutes prior to the exposure
to TGF-b1 (2.5 ng/mL) for 1 hour. Northern blotting was performed
and densitometric analysis of three independent experiments was per-
formed. The data are expressed as mean ± SD (N = 3). ∗P < 0.05 vs.
control; ∗∗P < 0.05 vs. TGF-b1.
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Fig. 4. Blockade of extracellular-regulated
kinase (ERK) kinase (MEK) activity does
not influence transforming growth factor-
b1 (TGF-b1)–induced Smad nuclear accu-
mulation and DNA binding to palindromic
Smad binding element (SBE) in rat plas-
minogen activator inhibitor-1 (PAI-1) pro-
moter. Cells were incubated with or with-
out PD98059 (10 lmol/L) for 90 minutes
prior to the exposure to TGF-b1 (2.5 ng/mL)
for 1 hour. (A) Immunocytochemistry was
performed with anti-Smad2/3 antibody. (B)
Nuclear proteins were subjected to sodium
dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). Immunoblotting
was performed using anti-Smad2/3 and Smad4
antibodies. The membrane was rehybridized
with nucleoporin p62 antibody. Densitomet-
ric analysis in three independent experiments
was performed. The data are expressed as
mean ± SD (N = 3). ∗P < 0.01 vs. con-
trol. (C) Cells were stimulated with TGF-b1
for 1 hour. Nuclear extracts from cells were
subjected to electrophoretic mobility shift as-
say (EMSA) using a [c32P] -labeled double-
stranded oligonucleotide (−280/−251) in rat
PAI-1 promoter containing an 8 bp palin-
dromic SBE. Supershift assay and competi-
tion experiment were performed as indicated.
(D) Cells were incubated with or without
PD98059 for 90 minutes prior to the exposure
to TGF-b1 for 1 hour. EMSA was performed
as described above. Abbreviations are: S.S.,
supershift; S.B., shifted band; N.B., nonspecific
band. A representative one of three indepen-
dent experiments is shown.
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Fig. 5. Transforming growth factor-b1 (TGF-
b1) stimulates rat plasminogen activator
inhibitor-1 (PAI-1) promoter activity through
the activator protein-1 (AP-1)–like sequence
but not palindromic Smad binding element
(pal. SBE). (A) Reporter constructs used in
this study are depicted. (B) Each of the re-
porter plasmids (0.5 lg) and cytomegalovirus
(CMV)-LacZ plasmid (0.25 lg) were cotrans-
fected into rat mesangial cells. Cells were
treated with TGF-b1 (2.5 ng/mL) for 16 hours
before harvesting for luciferase assay and
b-galactosidase activity measurement. Error
bars indicate SD for experiments performed
in triplicate. (C) TGF-b1 stimulates AP-1
DNA binding to the AP-1–like sequence in a
extracellular-regulated kinase (ERK) kinase
(MEK)-dependent manner. Cells were stim-
ulated with TGF-b1 for 1 hour. Nuclear pro-
teins were subjected to electrophoretic mobil-
ity shift assay (EMSA) using a [c32P]-labeled
double-stranded oligonucleotide (−46/−75)
in rat PAI-1 promoter containing AP-1–like
sequence. Competition study was performed
as described. (D) Cells were incubated with
or without PD98059 for 90 minutes prior to
the exposure to TGF-b1 for 1 hour. EMSA
was performed as described above. Abbrevi-
ations are: S.B., shifted band; N.B., nonspecific
band. A representative one of three indepen-
dent experiments is shown. (E) PAI-1 reporter
construct B (0.5 lg) along with Smad3A or
Smad3D plasmid (0.25 lg) was cotransfected
into rat mesangial cells. Cells were treated
with TGF-b1 (2.5 ng/mL) for 16 hours before
harvesting for luciferase and b-galactosidase
activity assays. Error bars indicate SD for ex-
periments performed in triplicate. (F) Rat
mesangial cells transfected with Smad3A, or
Smad3D plasmid (0.25 lg) were stimulated
with TGF-b1 (2.5 ng/mL) for 1 hour. A rep-
resentative Northern blot from among three
independent experiments is shown.
constructs used in this study are diagrammed in Figure
5A. As shown in Figure 5B, the deletion study of rat
PAI-1 promoter revealed that TGF-b1 stimulated the re-
porter activities in construct A and construct B as com-
pared with the activities in untreated cells. To assess
whether this AP-1–like sequence is a functional element,
reporter analysis using mutated construct in the AP-1–
like sequence was performed. Both basal and TGF-b1–
induced reporter activities were suppressed by the substi-
tution of TGTGTTTG for TGAGTTCA in the AP-1–like
binding site (Fig. 5B, construct C). TGF-b1–induced re-
porter activities were observed (Fig. 5B, construct D), in
which the palindromic SBE was mutated (GTCTAGAC
to CTCTAGAC). The 30 bp oligonucleotide composed
of mutated palindromic SBE did not form a complex
with Smads in EMSA performed using nuclear extract of
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Fig. 5. (continued)
TGF-b1–stimulated mesangial cells (data not shown). Fi-
nally, in the double mutated construct of SBE and AP-1–
like sequence (Fig. 5B, construct E), the basal and TGF-
b1–induced reporter activities were suppressed. These
results suggest that the AP-1–like sequence located in
the proximal region (−62 to −55) of rat PAI-1 promoter,
but not palindromic SBE, is an important regulatory ele-
ment for basal and TGF-b1–induced rat PAI-1 promoter
activity.
We next examined whether this AP-1–like sequence
(TGAGTTCA) located between −62 and −55 in rat
PAI-1 promoter is the target for TGF-b1–induced MEK-
ERK–derived AP-1 complex. EMSA using a 30 bp
oligonucleotide (−46/−75) in the rat PAI-1 promoter
containing this AP-1–like sequence revealed that TGF-
b1 stimulated the DNA binding activities of nuclear pro-
teins to this probe in mesangial cells (Fig. 5C). This band
was abolished by the addition of an excess amount of
the unlabeled oligonucleotides containing the consensus
AP-1 binding site (TGAGTCA) or AP-1–like sequence
(TGAGTTCA), but not by the addition of mutated AP-
1–like sequence (TGTGTTTG), suggesting that TGF-
b1–induced AP-1 complex can bind this AP-1–like
sequence. As shown in Figure 5D, TGF-b1–induced
DNA binding of nuclear proteins to this probe was sup-
pressed by the addition of PD98059, indicating that TGF-
b1–activated ERK stimulates rat PAI-1 gene expression
by increasing AP-1 DNA binding activity to the AP-1–
like sequence in the rat PAI-1 promoter. Finally, we exam-
ined the effects of overexpression of dominant-negative
Smad3 constructs (Smad3A and Smad3D) on promoter
activity and mRNA expression of PAI-1 to confirm that
the Smads pathway is not involved in TGF-b–induced
PAI-1 expression in rat mesangial cells. As shown in Fig-
ure 5E and F, Smad3A and Smad3D did not affect PAI-1
reporter activity or PAI-1 mRNA expression in the pres-
ence or absence of TGF-b1.
IFN-c inhibits TGF-b1–induced PAI-1 mRNA
expression by suppressing ERK-AP-1 in rat
mesangial cells
To further confirm the important role of the ERK-AP-1
pathway in the regulation of the rat PAI-1 gene, we exam-
ined the inhibitory effect of IFN-c on TGF-b signaling.
When cells were incubated with indicated concentrations
of IFN-c for 3 hours prior to TGF-b1 stimulation, TGF-
b1–induced PAI-1 mRNA expression was significantly
inhibited by IFN-c (Fig. 6A). We also demonstrated that
IFN-c inhibited TGF-b–induced ERK phosphorylation
(Fig. 6B) and AP-1 DNA binding activity (Fig. 6C). How-
ever, pretreatment with IFN-c did not affect TGF-b–
induced nuclear translocation of Smad2/3 (Fig. 6D) or
Smads DNA binding activities (Fig. 6E). Since previ-
ous studies suggested that IFN-c inhibits TGF-b–induced
gene expression through stimulating Smad7 expression in
other types of cells [24], we also examined the effect of
IFN-c on smad7 expression. As shown in Figure 7, the
expression of Smad7 was not changed when cells were
treated with IFN-c alone (Fig. 7A), and pretreatment with
IFN-c did not affect TGF-b–induced Smad7 expression
(Fig. 7B).
DISCUSSION
In the present study, we examined the roles of the
MAPK and Smad pathways in TGF-b1–induced rat PAI-
1 gene expression. TGF-b1 stimulated both pathways in
rat glomerular mesangial cells. We demonstrated that the
target sequences of these two pathways are separately lo-
cated in the proximal region of the rat PAI-1 promoter.
TGF-b1–induced AP-1 DNA binding to the AP-1–like
sequence, but not Smad binding to the palindromic SBE,
was involved in TGF-b1–induced rat PAI-1 promoter ac-
tivation. Furthermore, IFN-c inhibited TGF-b1–induced
PAI-1 mRNA expression through selectively suppress-
ing the MAPK-AP-1 pathway. These findings, for the first
time, suggest that MAPK-AP-1 activation is essential for
TGF-b1–induced rat PAI-1 gene expression and that this
regulation is unique to rat mesangial cells.
Since sequence comparison between human and rat
PAI-1 promoters has revealed that the region 780 bp
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Fig. 6. Interferon-c (IFN-c) inhibits transforming growth factor-b1 (TGF-b1)–induced plasminogen activator inhibitor-1 (PAI-1) mRNA expression
through the extracellular-regulated kinase-activator protein-1 (ERK-AP-1) pathway in rat mesangial cells. (A) IFN-c inhibited PAI-1 mRNA
expression induced by TGF-b1. Cells were pre-incubated with IFN-c at the indicated concentrations for 3 hours, followed by TGF-b1 stimulation
for 1 hour. (B) IFN-c inhibited TGF-b1–activated ERK phosphorylation. Cells were treated in the presence or absence of 10 ng/mL of IFN-c for 3
hours, followed by TGF-b1 stimulation for 10 minutes. (C) Nuclear extracts were incubated with [c32P] end-labeled AP-1 consensus oligonucleotide
probe, and electrophoretic mobility shift assay (EMSA) was performed. The arrow indicates the specific binding of AP-1. (D) IFN-c did not affect
the TGF-b1–induced Smad pathway. Cells were pretreated with or without 10 ng/mL of IFN-c for 3 hours, followed by TGF-b1 stimulation for
60 minutes. The data are expressed as mean ± SD (N = 3). ∗P < 0.01 vs. control. (E) Nuclear extracts were incubated with a [c32P] end-labeled
rat Smad binding element (SBE) oligonucleotide probe and were subjected to electrophoresis on a 4% polyacrylamide gel. The short horizontal
line indicates the specific binding of SBE. Abbreviations are: S.B., shifted band; N.B., nonspecific band. A representative one of three independent
experiments is shown.
upstream from the TATA box of rat PAI-1 promoter is
only 63% identical to the human sequence, it remains to
be elucidated how rat PAI-1 gene is regulated by TGF-b .
In this study, we identified the TGF-b1 responsive se-
quences in the rat PAI-1 promoter and found that the
AP-1–like sequence located in the proximal region (−62
to −55) of the promoter is important for basal and
TGF-b1–induced rat PAI-1 promoter activation. Further-
more, we also found that TGF-b1–stimulated AP-1 com-
plex could bind to this AP-1–like sequence in a MEK-
dependent manner. This AP-1–like sequence, TGAGTT
CA, is also conserved in the mouse and human PAI-1
promoters [5, 25], and phorbol 12-myristate 13-acetate
(PMA)- or fibrin fragment–induced AP-1 complexes
were shown to bind to this sequence and to stimulate
human PAI-1 promoter activity [19, 26]. Therefore, this
AP-1–like sequence in the PAI-1 promoter could be a
universal sequence which can respond to the activation
of MAPKs.
Recent studies suggest that the activation of the
MEK-ERK pathway by mitogenic stimulation or the ec-
topic expression of oncogenic Ras modulates Smad ac-
tivities [20, 21]. However, in a human keratinocyte line,
HaCa T cells, the expression of constitutively active MEK
did not affect TGF-b1–induced Smad3 nuclear accumu-
lation [27]. These reports indicated that the modulation of
Smads activities by the MEK-ERK pathway may be cell
type–specific or depend on the degree of activation of
this pathway. However, it has not been clarified whether
the MEK-ERK pathway activated by TGF-b1 modu-
lates Smad activity. In this study, the blockade of MEK
activity completely suppressed TGF-b1–induced ERK
phosphorylation (data not shown) and its downstream
signals without affecting TGF-b1–induced endogenous
Smad dynamics, including nuclear translocation and their
DNA binding activities. Our findings suggest that TGF-
b1–induced activation of the MEK-ERK pathway could
be distinct from Smad signaling in rat mesangial cells.
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Fig. 6. (continued)
Human Smad3 and Smad4 have been reported to
preferentially bind to GACACC, GTCTAGAC, or
AG(C/A)CAGACA sequences, and a series of three of
the last sequence, termed a CAGA box, is present in the
human PAI-1 promoter [10]. Furthermore, a CAGA box-
like sequence, GTCTGGAC, located at between −688
and −660 in the human PAI-1 promoter, has also been
newly identified as a binding site for Smad3 and Smad4
[22]. The binding of Smads to these sequences is consid-
ered to be important for TGF-b–induced activation of
human PAI-1 promoter. Similar findings were obtained
in murine cells. Piek et al [28] reported that fibroblasts
derived from Smad2- or Smad3-deficient mice exhibited
the inhibition of PAI-1 mRNA by TGF-b1. The inhibi-
tion of Smad signaling by dominant-negative Smad4 or
bone morphogenetic protein (BMP) suppressed TGF-
b1–induced PAI-1 expression in murine mesangial cells
[29, 30].
In our search for the rat PAI-1 promoter sequence, we
found two putative SBEs. One had a high degree of sim-
ilarity to the newly identified Smad3 and Smad4 binding
site in human PAI-1 promoter located at −626 to −596,
and the other was an 8 bp palindromic SBE (GTCTA-
GAC) located at −267 to −260, which is not conserved in
humans. In these two putative SBEs, TGF-b1 can stimu-
late endogenous Smads binding only to the palindromic
SBE located at −267 to −260. However, our study re-
vealed that this palindromic SBE is not involved in the
rat PAI-1 promoter activation. These results suggest that
the mechanisms involved in TGF-b–induced PAI-1 pro-
moter activation differ in humans and rats.
The regulation of certain other ECM proteins has been
extensively studied. It was demonstrated that TGF-b1
induced alpha 2 (I) collagen expression via Smad path-
way in certain cells, including human mesangial cells
[31, 32]. In contrast, we have previously reported that
TGF-b1 stimulated fibronectin expression via a MAPK-
dependent pathway in rat mesangial cells [33]. Consis-
tent with this observation, it has been shown that TGF-
b1 stimulated fibronectin in a Smad-independent manner
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Fig. 7. Interferon-c (IFN-c) did not affect Smad7 mRNA expression in
rat mesangial cells. (A) IFN-c alone did not affect Smad7 mRNA expres-
sion. Cells were incubated with IFN-c for the indicated intervals. (B)
IFN-c did not affect Smad7 mRNA expression induced by transform-
ing growth factor-b1 (TGF-b1). Cells were preincubated with IFN-c at
the indicated concentrations for 3 hours, followed by TGF-b1 stimula-
tion for 1 hour. Northern blotting was performed as described above.
A representative one of three independent experiments is shown.
[29, 34]. Taken together, these data suggest that TGF-b
stimulates various gene expressions related to ECM pro-
teins through different pathways in various cell types.
Previous studies showed that TGF-b and IFN-c ex-
ert opposite effects on diverse cellular functions. IFN-c
inhibited TGF-b signaling through suppressing TGF-b–
induced regulatory Smad activation. One possibility is
that IFN-c can induce Smad7 gene expression via the
Stat1 alpha pathway leading to modification of TGF-b
receptors [24, 35]. However, the expression of Smad7 in-
duced by IFN-c was observed in cells of epithelial origin,
including HepG2 and U4A cells, but not in fibroblasts. In-
deed, in the present study, we did not find any increase of
Smad7 expression induced by IFN-c. The result indicates
that IFN-c inhibits TGF-b–induced PAI-1 expression in
a Smad7-independent manner in rat mesangial cells. An-
other possible mechanism is competition between acti-
vated Stat1 alpha and Smad3 for interaction with the
nuclear coactivator p300/CBP [36, 37]. However, we did
not find any effect of IFN-c on the nuclear translocation
or the DNA binding activities of Smad proteins. Alter-
natively, we found that IFN-c inhibited TGF-b–induced
ERK phosphorylation and AP-1 DNA binding activity.
Thus, the ERK-AP-1 pathway, but not the Smad path-
way, mediates the inhibitory effect of IFN-c on TGF-b1–
induced PAI-1 gene expression in rat mesangial cells.
CONCLUSION
We propose a unique mechanism by which TGF-
b1 induces PAI-1 expression through the MAPK-AP-1
pathway in rat glomerular mesangial cells. These results
suggest that TGF-b–induced PAI-1 gene expression dif-
fers depending on the species.
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